Register Login

Agios Pharmaceuticals Inc (AGIO)

(90% Positive) Agios Pharmaceuticals Inc (AGIO) Announces Enrollment Update for anticipated Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 8:50 p.m.

    📋 Agios Pharmaceuticals Inc (AGIO) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 07:11:20

    Event Type: Clinical Trial Update

    Event Details:

    Agios Pharmaceuticals Inc (AGIO) Announces Clinical Trial Update Agios Pharmaceuticals Inc (AGIO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: anticipated, medicines
    • Diseases/Conditions: peak global salesCAMBRIDGE
    • Collaboration: AQVESME
    • Updated Timeline: December 2025
      • anticipated in first quarter of 2026
      • targeting TMPRSS6 as a potential treatment for PV, in the first half of 2026

    🔬 Clinical Development Pipeline (Agios Pharmaceuticals Inc):

    Product Type Development Stage Therapeutic Area Source
    AG-236 DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    AG-181 DRUG Phase PHASE1 Phenylketonuria ClinicalTrials.gov
    Placebo for Treatment C DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Tebapivat Matched Placebo DRUG Phase PHASE2 Sickle Cell Disease ClinicalTrials.gov
    Tebapivat DRUG Phase PHASE2 Sickle Cell Disease ClinicalTrials.gov
    Mitapivat DRUG Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ClinicalTrials.gov
    Placebo Matching Mitapivat DRUG Phase PHASE3 Non-Transfusion-dependent Alpha-Thalassemia ClinicalTrials.gov
    Mitapivat-matching placebo DRUG Phase PHASE3 Pediatric Pyruvate Kinase Deficiency ClinicalTrials.gov
    AG-348 DRUG Phase PHASE2 Thalassemia ClinicalTrials.gov
    Placebo DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Blood Draw PROCEDURE Preclinical Pyruvate Kinase Deficiency ClinicalTrials.gov
    Ivosidenib DRUG Phase PHASE1 IDH1 Mutation Myeloid Neoplasms ClinicalTrials.gov
    AG-120 DRUG Phase PHASE2 Chondrosarcoma ClinicalTrials.gov
    LB-102 DRUG Phase PHASE2 Schizophrenia ClinicalTrials.gov
    AG221 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    AG120 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    [14C]-AG-120 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    ivosidenib (AG-120) DRUG Preclinical Acute Myeloid Leukemia ClinicalTrials.gov
    AG-519 DRUG Phase PHASE1 Anemia ClinicalTrials.gov
    [13C6]AG-348 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Itraconazole DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    AG-120 (Ivosidenib) DRUG Phase PHASE1 Hepatic Impairment ClinicalTrials.gov
    AG-348 Sequence B DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    AG-348 Sequence A DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Lamotrigine DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    AG-881 DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    AG-636 DRUG Phase PHASE1 Lymphoma ClinicalTrials.gov
    AG881 DRUG Phase PHASE1 Acute Myeloid Leukemia (AML) ClinicalTrials.gov
    mitapivat sulfate DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    rifampin DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    [13C315N3]AG-881 DRUG Phase PHASE1 Healthy Male Participants ClinicalTrials.gov
    Mitapivat 300 mg DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Placebo for Treatment B DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Mitapivat 100 mg DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Placebo for Treatment A DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Omeprazole DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    AG881 Formulation 2 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    AG881 Formulation 1 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Mitapivat coated granules DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Mitapivat tablets DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Mitapivat tablet DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    AG-946 Matched Placebo DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    AG-946 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    [13C2,15N3]-tebapivat DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    [14C]-tebapivat DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    ivosidenib and nivolumab DRUG Phase PHASE2 Advanced Solid Tumor ClinicalTrials.gov
    Enasidenib DRUG Phase PHASE1 Hematologic Neoplasms ClinicalTrials.gov
    Midazolam DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Agios Pharmaceuticals Inc
    • Ticker Symbol: AGIO

Search

News categories